FDA menopause hormone therapy label changes, 2026: what actually changed

On February 12, 2026, the FDA approved labeling changes for six menopausal hormone therapy products, spanning all four categories of systemic and topical hormone therapy: combination estrogen-progestogen therapy, estrogen-alone therapy, progestogen-alone therapy used alongside systemic estrogen, and topical vaginal estrogen.^[1]The change removes boxed-warning language describing increased risk of cardiovascular disease, breast cancer, and probable dementia, warnings that had been on hormone therapy labels since shortly after the 2002 Women’s Health Initiative (WHI) trial results were published.^{[1] [5]}

The February action was the final step in a process that started earlier: the FDA convened a multidisciplinary expert panel on July 17, 2025, to review the benefit-risk evidence, and HHS announced in November 2025 that it would begin removing the warnings following that review and a public comment period.^{[2] [4]} As of this writing, roughly 29 companies had submitted proposed labeling updates for FDA review, meaning individual product labels roll out on their own timeline rather than all at once.^[1]

For the fuller picture of what major clinical guidelines say about who benefits from hormone therapy and how the risk-benefit balance shifts with regimen, route, and timing, see our companion article, Menopause and hormone therapy: what the evidence says. This piece focuses specifically on the regulatory label change itself: what triggered it, and how well the evidence behind it actually holds up.

The boxed warnings did not appear arbitrarily. They followed the 2002 publication of the WHI estrogen-plus-progestin trial, a large randomized, placebo-controlled trial in more than 16,000 healthy postmenopausal women that was stopped early after an independent monitoring board found the overall risk-benefit profile unfavorable, driven mainly by increased risk of invasive breast cancer, coronary heart disease, stroke, and blood clots.^[5] That trial was designed specifically because the observational evidence available before 2002, cohort and case-control studies suggesting hormone therapy prevented heart disease and other conditions, had never been tested in a large randomized trial. WHI was that test, and its results were more mixed than the preceding observational literature had suggested.

That history matters for reading the 2026 label change, because the FDA’s current position is not that WHI was wrong. It is that WHI enrolled women who were, on average, older and further from menopause onset than the women who typically start hormone therapy for symptom relief today, and that risk looks different depending on when therapy starts.^[1]That timing argument has real support in the data, covered next, but it is a narrower claim than “the original warnings were a mistake.”

The strongest randomized evidence behind the FDA’s timing argument concerns fractures. In the WHI trial itself, combined estrogen-progestin therapy reduced hip fracture risk by a statistically significant 34% (hazard ratio 0.66) compared with placebo.^[5] That is genuine, randomized, trial-level evidence, not an observational association.

Mortality is a different story. A 2017 analysis of WHI participants followed for a cumulative 18 years found no significant difference in all-cause mortality between the hormone therapy and placebo groups overall (27.1% versus 27.6%; hazard ratio 0.99).^[6]Looking specifically at women who started therapy in their 50s, there was a statistically significant mortality benefit during the years they were actively taking the drug (the “intervention phase”), but that trend was no longer statistically significant once the researchers looked at cumulative mortality across the full 18-year follow-up period.^[6]

The HHS/FDA November 2025 announcement, which frames the case for removing the warnings, states that women starting hormone therapy within 10 years of menopause or before age 60 “may reduce their risk of cardiovascular diseases by as much as 50%,” reduce Alzheimer’s disease risk by 35%, and reduce bone fractures by 50 to 60%, framed as findings from “randomized studies.”^[2]We checked what each number actually links to in the agency’s own release.

The 50% cardiovascular figure links to a 1991 JAMA article by Barrett-Connor and Bush, a narrative review summarizing observational cohort studies of estrogen and coronary heart disease, not a randomized trial.^[7]The 35% Alzheimer’s figure links to a 1996 Archives of Internal Medicine paper by Paganini-Hill and Henderson, an observational cohort study (the Leisure World cohort) of estrogen use and Alzheimer disease diagnosis, also not a randomized trial.^[8] The 50-to-60% fracture figure links to a 1980 New England Journal of Medicine case-control study by Weiss and colleagues, again an observational design.^[9]

This is not a minor citation slip. These three studies are representative of exactly the kind of encouraging observational literature, from the 1980s and 1990s, that led clinicians to prescribe hormone therapy widely for disease prevention before the WHI randomized trial was run specifically to test those observational findings and produced a more mixed result.^[5] Citing that older observational literature to support removing a warning that exists because a later randomized trial complicated that same literature is a real tension, even though it does not mean the underlying decision to reconsider the warnings is wrong. It means the specific numbers repeated in press coverage of this label change deserve more scrutiny than a press release affords them.

The boxed warning for endometrial cancer remains on systemic estrogen-only products intended for women who still have a uterus, since unopposed estrogen is a well-established cause of endometrial hyperplasia and cancer in that population; this is the one warning the February 2026 action explicitly left in place.^[1] The underlying safety data on venous thromboembolism and stroke risk, and the well-documented difference in clot risk between oral and transdermal estrogen, are unchanged by this label action; that route-dependent risk difference is covered in more depth in our companion article on the broader evidence base.

In practice, this label change mostly affects how hormone therapy is discussed and disclosed, not who is actually a good candidate for it. Clinical guidelines already recommend hormone therapy primarily for healthy, symptomatic women within about 10 years of menopause onset or under 60, which is the same population the FDA’s timing argument centers on.^[1] Removing a boxed warning may make clinicians and patients less hesitant to discuss hormone therapy for appropriate candidates, which the FDA and expert panel argue was a genuine problem with the old, broader warning language.^[4] It does not change the individualized calculation for women with a personal history of breast cancer, blood clots, stroke, heart attack, or liver disease, who remain a different discussion entirely.

A less prominent label warning does not remove the need to watch for the safety signals that remain well-documented for hormone therapy.

The FDA genuinely reassessed menopausal hormone therapy labeling in 2026, and the core argument that risk and benefit depend heavily on when a woman starts therapy has real randomized-trial support, most clearly for fracture risk. But the specific benefit percentages the agency repeated in its own announcement trace back to decades-old observational studies rather than new trials, and the mortality claim most often repeated in coverage of this change is weaker than it sounds once you look at the cumulative 18-year WHI follow-up data. A loosened warning label is real regulatory news worth understanding, not a new, settled verdict that hormone therapy prevents heart disease or dementia. See how we grade the strength of evidence across topics in our editorial and evidence standards, and browse the rest of our Hormone & Vitality coverage as it grows.

None of this replaces an individual conversation with a prescribing clinician who knows your symptoms, personal and family history, and cardiovascular and cancer risk factors. It reflects what the FDA, HHS, and the underlying trial data actually say: a real label change, built on an uneven mix of strong and weak evidence.